Surgeons and health system leaders are voicing concerns about the unknown long-term risks of glucagon-like peptide-1 receptor agonists, such as Ozempic, Wegovy and Saxenda.
Read the full post on Becker's Hospital Review - Healthcare News
Surgeons raise concerns about Ozempic, other GLP-1s
